Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
PLSE Quote, Financials, Valuation and Earnings
Last price:
$14.40
Seasonality move
:
31.15%
Day range:
$14.41 - $15.01
52-week range:
$12.56 - $25.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11,397.40x
P/B ratio:
10.78x
Volume:
64.6K
Avg. volume:
197K
1-year change:
-18.93%
Market cap:
$999.7M
Revenue:
--
EPS (TTM):
-$1.14
Analysts' Opinion
-
Consensus RatingPulse Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.00, Pulse Biosciences, Inc. has an estimated upside of 48.05% from its current price of $14.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $14.86.
Fair Value
-
According to the consensus of 1 analyst, Pulse Biosciences, Inc. has 48.05% upside to fair value with a price target of $22.00 per share.
PLSE vs. S&P 500
-
Over the past 5 trading days, Pulse Biosciences, Inc. has overperformed the S&P 500 by 2.74% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pulse Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pulse Biosciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Pulse Biosciences, Inc. reported revenues of $86K.
Earnings Growth
-
Pulse Biosciences, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Pulse Biosciences, Inc. reported earnings per share of -$0.29.
Enterprise value:
912.4M
EV / Invested capital:
9.07x
Price / LTM sales:
11,397.40x
EV / EBIT:
--
EV / Revenue:
10,608.91x
PEG ratio (5yr expected):
-0.32x
EV / Free cash flow:
-18.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.3M
Return On Assets:
-63.39%
Net Income Margin (TTM):
-86898.84%
Return On Equity:
-73.32%
Return On Invested Capital:
-67.74%
Operating Margin:
-23682.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -$9K | -- | $86K | -- | $86K | |
| Gross Profit | -$2.5M | -$1.1M | -$1.3M | -$267K | -$449K | |
| Operating Income | -$39.8M | -$48.5M | -$77.1M | -$13.7M | -$20.4M | |
| EBITDA | -$38.6M | -$47.4M | -$76M | -$13.4M | -$20.1M | |
| Diluted EPS | -$0.92 | -$0.81 | -$1.14 | -$0.21 | -$0.29 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49.2M | $71.2M | $51.6M | $80.4M | $97.2M | |
| Total Assets | $67.1M | $87.6M | $65.9M | $93M | $108.8M | |
| Current Liabilities | $9.5M | $7M | $5.4M | $6.7M | $9.7M | |
| Total Liabilities | $19.8M | $81.4M | $13.8M | $13.9M | $16.1M | |
| Total Equity | $47.4M | $6.2M | $52.1M | $79.1M | $92.7M | |
| Total Debt | $11.3M | $74.5M | $8.4M | $7.2M | $6.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34.2M | -$34M | -$48.5M | -$9M | -$13M | |
| Cash From Investing | -$119K | -$115K | -$283K | -$38K | -$62K | |
| Cash From Financing | $15.6M | $62.7M | $65M | $61.9M | $2M | |
| Free Cash Flow | -$34.3M | -$34.1M | -$48.8M | -$9.1M | -$13.1M | |
PLSE
Sector
Market Cap
$999.7M
$27.8M
Price % of 52-Week High
59.44%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-5.44%
-1.55%
1-Year Price Total Return
-18.93%
-17.47%
Beta (5-Year)
1.806
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.61
200-day SMA
Sell
Level
$16.05
Bollinger Bands (100)
Sell
Level
14.08 - 17.62
Chaikin Money Flow
Sell
Level
-59.8K
20-day SMA
Buy
Level
$14.00
Relative Strength Index (RSI14)
Buy
Level
55.29
ADX Line
Buy
Level
22.76
Williams %R
Neutral
Level
-38.7324
50-day SMA
Sell
Level
$15.08
MACD (12, 26)
Buy
Level
3.90
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
391.7K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (31.4438)
Sell
CA Score
(Annual)
Level (-1.5252)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.358)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.
Stock Forecast FAQ
In the current month, PLSE has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PLSE average analyst price target in the past 3 months is $22.00.
-
Where Will Pulse Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pulse Biosciences, Inc. share price will rise to $22.00 per share over the next 12 months.
-
What Do Analysts Say About Pulse Biosciences, Inc.?
Analysts are divided on their view about Pulse Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pulse Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Pulse Biosciences, Inc.'s Price Target?
The price target for Pulse Biosciences, Inc. over the next 1-year time period is forecast to be $22.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PLSE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pulse Biosciences, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PLSE?
You can purchase shares of Pulse Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pulse Biosciences, Inc. shares.
-
What Is The Pulse Biosciences, Inc. Share Price Today?
Pulse Biosciences, Inc. was last trading at $14.40 per share. This represents the most recent stock quote for Pulse Biosciences, Inc.. Yesterday, Pulse Biosciences, Inc. closed at $14.86 per share.
-
How To Buy Pulse Biosciences, Inc. Stock Online?
In order to purchase Pulse Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PLSE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PLSE
Sector
P/E ratio
--
23.89x
PEG ratio
-0.32x
-0.01x
P/B ratio
10.78x
1.82x
Price / LTM sales
11,397.40x
1.60x
Growth Metrics
PLSE
Sector
Revenue growth
--
4.62%
Earnings growth
-38.58%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
PLSE
Sector
Profitability FY 2024
-$1.2M
$3.5M
Return on invested capital
-67.74%
-31.77%
Return on assets
-63.39%
-27.96%
Return on equity
-73.32%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
4
Balance Sheet
PLSE
Sector
Total cash
$95.2M
$26.3M
Short term investments
--
$25.7M
Total assets
$134.1M
$78M
Long term debt
$6.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 3.73% over the past day.
Buy
60
AAOI alert for Dec 26
Applied Optoelectronics, Inc. [AAOI] is down 9.39% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
